Johnson & Johnson (NYSE:JNJ) Position Boosted by Jump Financial LLC

Jump Financial LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2,001.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,717 shares of the company's stock after purchasing an additional 30,208 shares during the quarter. Jump Financial LLC's holdings in Johnson & Johnson were worth $4,587,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. IFS Advisors LLC boosted its holdings in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after purchasing an additional 100 shares during the last quarter. WealthTrak Capital Management LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter worth about $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $29,000. Bay Harbor Wealth Management LLC purchased a new stake in Johnson & Johnson during the 4th quarter worth about $32,000. Finally, Conquis Financial LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $33,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Up 2.3 %

Shares of Johnson & Johnson stock traded up $3.51 during trading hours on Friday, hitting $157.42. The company had a trading volume of 10,972,370 shares, compared to its average volume of 7,953,112. The company's 50-day moving average is $159.49 and its two-hundred day moving average is $155.03. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a market cap of $379.37 billion, a P/E ratio of 23.67, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a $1.30 dividend. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.30%. The ex-dividend date is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is currently 74.59%.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Argus raised Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Stifel Nicolaus decreased their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a report on Thursday, January 23rd. Wells Fargo & Company dropped their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a report on Thursday, January 23rd. Finally, Barclays reduced their price target on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a report on Thursday. Nine research analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $171.72.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.